logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Shukui Qin

Nanjing Medical University
H指数:76
被引数:5.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma

杜伯-308研究方案：一项随机、开放标签、无缝II/III期试验的合理性与适应性设计，比较伊帕罗利单抗和图沃尼利单抗（QL1706）为基础方案与信迪利单抗联合贝伐珠单抗作为晚期肝细胞癌一线治疗的疗效

Future Oncology
IF2.6
2026-10-010
PRE
Fan Yang; Weikang Tao; Zihang Zhong; Jia Fan; Hao Yu; Shukui Qin
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)

CheckMate 9DW研究的通俗总结：纳武利尤单抗联合伊匹木单抗治疗不可切除的肝细胞癌（晚期肝癌）

Future Oncology
IF2.6
2026-04-140
PRE
Thomas Yau; Peter R Galle; Thomas Decaens; Bruno Sangro; Shukui Qin; Leonardo G da Fonseca; Hatim Karachiwala; Jean-Frederic Blanc; Joong-Won Park; Edward Gane; Matthias Pinter; Ana Matilla Peña; Masafumi Ikeda; David Tai; Armando Santoro; Gonzalo Pizarro; Chang-Fang Chiu; Michael Schenker; Aiwu He; Hong Jae Chon; Joanna Wojcik-Tomaszewska; Gontran Verset; Qi Qi Wang; Caitlyn Stromko; Jaclyn Neely; Prianka Singh; Maria Jesus Jimenez Exposito; Masatoshi Kudo
Chinese expert consensus on diagnosis and treatment of small gastrointestinal stromal tumors (2025 edition)

《小胃肠间质瘤（2025年版）诊断与治疗中国专家共识》

Cancer
IF5.1
2025-12-090
OAAI
Zhidong Gao MD; Chao Wang MD; Jian Li MD; Peng Zhang MD; Xin Wu MD; Yi Wang MD; Liming Zhang MD; Tao Chen MD; Bo Zhang MD; Ming Wang MD; Haoran Qian MD; Ye Zhou MD; Shijie Li MD; Yan Sun MD; Han Liang MD; Yulong He MD; Yong Li MD; Hui Cao MD; Shukui Qin MD; Lin Shen MD; Yingjiang Ye MD, PhD; Chinese Society of Clinical Oncology (CSCO) Expert Committee on Gastrointestinal Stromal Tumor
First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial

一线帕博利珠单抗联合化疗治疗HER2阴性胃或胃食管结合部腺癌：来自随机III期KEYNOTE-859试验的健康相关生活质量

European Journal of Cancer
IF7.1
2025-09-200
PRE
Maeve A. Lowery; Lucjan S. Wyrwicz; Do-Youn Oh; Kai-Keen Shiu; Patricio Yañez; Yuxian Bai; Min-Hee Ryu; Jeeyun Lee; Fernando Rivera; Gustavo Vasconcelos Alves; Marcelo Garrido; Manuel González Fernández; Jin Li; Timuçin Çil; Felipe Melo Cruz; Shukui Qin; Yanfen Guan; Adriana Valderrama; Sonal Bordia; Sun Young Rha
Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study

fruquintinib在中国结直肠癌患者中的安全性：一项来自IV期真实世界临床实践研究的年龄亚组分析

Therapeutic Advances in Medical Oncology
IF4.2
2025-09-010
OA
Yi Wang; Yifu He; Zhiqiang Wang; Haijun Zhong; Zuoxing Niu; Shujun Yang; Tao Zhang; Liangjun Zhu; Yongqian Shu; Jianjun Peng; Yan Song; Jian Li; Ying Yuan; Haibo Zhang; Gengsheng Yu; Yunqi Hua; Jianjun Xiao; Jianfei Fu; Yulong Zheng; Jingyu Zhu; Hua Xue; Xian Luo; Michael Shi; Weiguo Su; Jin Li; Shukui Qin
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma

LEAP-002研究：lenvatinib联合pembrolizumab对比lenvatinib单药作为晚期肝细胞癌一线治疗的健康相关生活质量分析

ESMO Open
IF8.3
2025-06-010
OA
R.S. Finn; M. Kudo; P. Merle; T. Meyer; S. Qin; M. Ikeda; R. Xu; J. Edeline; B.-Y. Ryoo; Z. Ren; A.-L. Cheng; P.R. Galle; S. Kaneko; H. Kumada; S. Kamble; J.M. Norquist; K. Mody; A. Wang; L. Dubrovsky; J.M. Llovet
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249.

[1] Sung H, Ferlay J, Siegel RL, 等. 全球癌症统计数据2020：185个国家36种癌症的全球发病率与死亡率GLOBOCAN估算. CA Cancer J Clin 2021;71:209-249.

JHEP REPORTS
IF7.5
2025-02-010
PRE
Finn, Richard S.; Gu, Kangsheng; Chen, Xi; Merle, Philippe; Lee, Kyung-Hun; Bouattour, Mohamed; Cao, Peiguo; Wang, Wei; Cheng, Ann-Lii; Zhu, Liangjun; Lim, Ho Yeong; Kudo, Masatoshi; Pan, Yueyin; Chang, Ting-Tsung; Edeline, Julien; Li, Wei; Yang, Ping; Li, Chen; Li, Jianfeng; Siegel, Abby B.; Qin, Shukui
Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)

EMERALD-1研究中基线肿瘤负荷对结局的影响：一项关于度伐利尤单抗（D）±贝伐珠单抗（B）联合经动脉化疗栓塞（TACE）在栓塞适应症的不可切除肝细胞癌（uHCC）中的III期研究

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Kudo, M.; Lencioni, R.; Erinjeri, J.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V. V.; Bouattour, M.; Dayyani, F.; Yoon, J-H.; Chiu, C-F.; Suttichaimongkol, T.; Decaens, T.; Griffin, R.; Morgan, C.; Ali, S. K.; Balaji, K.; Sangro, B.
Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)

EMERALD-1研究中的基线肿瘤负荷分层结果：一项评估度伐利尤单抗（D）联合或不联合贝伐珠单抗（B）与经动脉化疗栓塞术（TACE）治疗栓塞术适用型不可切除性肝细胞癌（uHCC）患者的III期、随机、安慰剂（PBO）对照研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Kudo, M.; Lencioni, R.; Erinjeri, J. P.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V.; Bouattour, M.; Dayyani, F.; Yoon, J-H.; Chiu, C-F.; Suttichaimongkol, T.; Decaens, T.; Griffin, R.; Morgan, C.; Ali, S. K.; Balaji, K.; Sangro, B.
A multicenter, prospective, non-interventional real-world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer
IMMUNITY INFLAMMATION AND DISEASE
IF2.7
2024-08-060
OAAI
Mao, Chenyu; He, Ye; Xu, Nong; Yan, Haijiao; Zhang, Ningling; Cheng, Gang; Jiang, Hua; Chen, Minbin; Chen, Yong; Wang, Xiaoguang; Gu, Yulan; Shen, Peng; Zhang, Guifang; Yan, Jun; Yang, Zhe; Ding, Lifang; Han, Zhengxiang; Wang, Zhanggui; Zhang, Junqi; Zheng, Weie; Wang, Jufeng; Qin, Shukui
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial

Fruquintinib联合紫杉醇与安慰剂联合紫杉醇治疗胃或胃食管交界处腺癌的比较: FRUTIGA随机3期试验

NATURE MEDICINE
IF50
2024-06-011
PRE
Wang, Feng; Shen, Lin; Guo, Weijian; Liu, Tianshu; Li, Jin; Qin, Shukui; Bai, Yuxian; Chen, Zhendong; Wang, Jufeng; Pan, Yueyin; Shu, Yongqian; Zhao, Fuyou; Cheng, Ying; Ye, Feng; Gu, Kangsheng; Zhang, Tao; Pan, Hongming; Zhong, Haijun; Zhou, Fuxiang; Qin, Yanru; Yang, Lei; Mao, Weidong; Li, Qiu; Dai, Wenxiang; Li, Wei; Wang, Shubin; Tang, Yong; Ma, Dong; Yin, Xianli; Deng, Yanhong; Yuan, Ying; Li, Man; Hu, Wenwei; Chen, Donghui; Li, Guoxin; Liu, Qiqi; Tan, Panfeng; Fan, Songhua; Shi, Michael; Su, Weiguo; Xu, Rui-Hua
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

卡博替尼联合阿特珠单抗与索拉非尼治疗晚期肝细胞癌 (COSMIC-312): 一项随机3期研究的最终结果

LANCET GASTROENTEROLOGY & HEPATOLOGY
IF38.6
2024-04-0119
PRE
Yau, Thomas; Kaseb, Ahmed; Cheng, Ann-Lii; Qin, Shukui; Zhu, Andrew X.; Chan, Stephen L.; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; Breder, Valery; Verset, Gontran; Gane, Edward; Borbath, Ivan; Rangel, Jose David Gomez; Ryoo, Baek-Yeol; Makharadze, Tamta; Merle, Philippe; Benzaghou, Fawzi; Milwee, Steven; Wang, Zhong; Curran, Dominic; Kelley, Robin Kate; Rimassa, Lorenza
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
LIVER CANCER
IF9.1
2024-01-103
OAAI
Qin, Shukui; Fang, Weijia; Ren, Zhenggang; Ou, Shuangyan; Lim, Ho Yeong; Zhang, Feng; Lee, Kin Chung; Choi, Hye Jin; Tong, Jiandong; Tao, Min; Xu, Aibing; Cheng, Ashley; Lu, Chang-Hsien; Chiu, Chang-Fang; Wahid, Mohamed Ibrahim Abdul; Kamble, Shital; Norquist, Josephine M.; Zhong, Wenyan; Li, Chen; Chen, Zhendong
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial

阿特珠单抗联合贝伐单抗与主动监测在切除或消融高危肝细胞癌患者中的比较 (IMbrave050): 一项随机、开放标签、多中心、3期试验

LANCET
IF88.5
2023-11-01144
PRE
Qin, Shukui; Chen, Minshan; Cheng, Ann-Lii; Kaseb, Ahmed; Kudo, Masatoshi; Lee, Han Chu; Yopp, Adam C.; Zhou, Jian; Wang, Lu; Wen, Xiaoyu; Heo, Jeong; Tak, Won Young; Nakamura, Shinichiro; Numata, Kazushi; Uguen, Thomas; Hsiehchen, David; Cha, Edward; Hack, Stephen P.; Lian, Qinshu; Ma, Ning; Spahn, Jessica H.; Wang, Yulei; Wu, Chun; Chow, Pierce K. H.
Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial

成纤维细胞生长因子受体 (FGFR) 共改变 (co-alt) 景观及其对二期开放标签单臂RAGNAR试验中erdafitinib (erda) 反应的影响

ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Loriot, Y.; Pant, S.; Witt, O.; Reardon, D. A.; Doi, T.; Qin, S.; Tabernero, J.; Iyer, G.; Massard, C.; Arnold, D.; Lugowska, I.; Carranza, O.; Gutierrez, M.; Winter, H.; Sweiti, H.; Thomas, S.; Gormley, M.; Zhang, J.; Triantos, S.; Schuler, M. H. H.

研究方向

暂未获取到该数据
Y
Yuxian Bai
H 指数:59论文数:366被引数:1.9万
M
Masatoshi Kudo
H 指数:143论文数:2,840被引数:12.4万
J
Jianming Xu
H 指数:56论文数:387被引数:2.6万
A
Ann‐Lii Cheng
H 指数:102论文数:1,290被引数:7.5万
Z
Zhenggang Ren
H 指数:58论文数:276被引数:1.3万
R
Richard S. Finn
H 指数:101论文数:764被引数:8.1万
H
Hongming Pan
H 指数:63论文数:371被引数:2.3万
程
程颖
H 指数:84论文数:1,042被引数:4.4万
L
Lin Shen
H 指数:62论文数:827被引数:2.6万
徐
徐瑞华
H 指数:104论文数:1,467被引数:5.3万